ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

States Spent Only 3.2% Of Settlement Money On Smoking Cessation.

November 21, 2008

HCT Survivors More Likely To Show Heart Disease Risk Factors

October 26, 2012

The Administration: Gore Marks 2nd Year of Tumor Gene Index, Honors Armstrong, Cancer Survivors

September 3, 1999

Survey Finds Misconceptions About Cancer Worldwide

August 29, 2008

Capitol Hill: Trial Results Represent Culmination of Research, Klausner Tells House

March 19, 1999

New Treatment Approaches for Leukemias Emerging From Early Clinical Trials

December 31, 2004